1. Fecal Metabolic Profiling of Breast Cancer Patients during Neoadjuvant Chemotherapy Reveals Potential Biomarkers
- Author
-
Nessrine Souai, Laetitia Shintu, Fabrice Tranchida, Amor Mosbah, Farhat Ben Ayed, Henda Raies, Ameur Cherif, Sonia Mezrioui, Oumaima Zidi, Soumaya Kouidhi, Amel Mezlini, Jean-Marc Sabatier, Institut de neurophysiopathologie (INP), and Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Oncology ,Male ,Proton Magnetic Resonance Spectroscopy ,Pharmaceutical Science ,Gut flora ,medicine.disease_cause ,Analytical Chemistry ,Feces ,0302 clinical medicine ,MESH: Least-Squares Analysis ,Drug Discovery ,MESH: Metabolomics ,metabolites ,0303 health sciences ,MESH: Proton Magnetic Resonance Spectroscopy ,Principal Component Analysis ,MESH: Middle Aged ,biology ,MESH: Feces ,Discriminant Analysis ,dysbiosis ,Middle Aged ,metabolomics ,Neoadjuvant Therapy ,3. Good health ,Chemistry (miscellaneous) ,030220 oncology & carcinogenesis ,Metabolome ,Molecular Medicine ,Female ,MESH: Biomarkers, Tumor ,MESH: Metabolome ,Metabolic Networks and Pathways ,medicine.medical_specialty ,MESH: Neoadjuvant Therapy ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Breast Neoplasms ,Article ,lcsh:QD241-441 ,03 medical and health sciences ,Breast cancer ,Metabolomics ,lcsh:Organic chemistry ,Internal medicine ,medicine ,MESH: Carbon-13 Magnetic Resonance Spectroscopy ,Biomarkers, Tumor ,Humans ,Physical and Theoretical Chemistry ,Carbon-13 Magnetic Resonance Spectroscopy ,Least-Squares Analysis ,MESH: Fatty Acids, Volatile ,030304 developmental biology ,MESH: Principal Component Analysis ,MESH: Humans ,gut microbiota ,business.industry ,breast cancer (BC) ,Organic Chemistry ,Cancer ,MESH: Discriminant Analysis ,biomarkers ,MESH: ROC Curve ,Omics ,medicine.disease ,biology.organism_classification ,Fatty Acids, Volatile ,MESH: Male ,ROC Curve ,MESH: Metabolic Networks and Pathways ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,business ,Carcinogenesis ,Dysbiosis ,MESH: Female ,MESH: Breast Neoplasms - Abstract
International audience; Breast cancer (BC) is the most common form of cancer among women worldwide. Despite the huge advancements in its treatment, the exact etiology of breast cancer still remains unresolved. There is an increasing interest in the role of the gut microbiome in modulating the anti-cancer therapeutic response. It seems that alteration of the microbiome-derived metabolome potentially promotes carcinogenesis. Taken together, metabolomics has arisen as a fascinating new omics field to screen promising metabolic biomarkers. In this study, fecal metabolite profiling was performed using NMR spectroscopy, to identify potential biomarker candidates that can predict response to neoadjuvant chemotherapy (NAC) for breast cancer. Metabolic profiles of feces from patients (n = 8) following chemotherapy treatment cycles were studied. Interestingly, amino acids were found to be upregulated, while lactate and fumaric acid were downregulated in patients under the second and third cycles compared with patients before treatment. Furthermore, short-chain fatty acids (SCFAs) were significantly differentiated between the studied groups. These results strongly suggest that chemotherapy treatment plays a key role in modulating the fecal metabolomic profile of BC patients. In conclusion, we demonstrate the feasibility of identifying specific fecal metabolic profiles reflecting biochemical changes that occur during the chemotherapy treatment. These data give an interesting insight that may complement and improve clinical tools for BC monitoring.
- Published
- 2021